ProSomnus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:35 pm EST
Share
ProSomnus, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 7.07 million compared to USD 5 million a year ago. Net loss was USD 11.24 million compared to USD 3.55 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.14 a year ago. Diluted loss per share from continuing operations was USD 0.7 compared to USD 0.14 a year ago.
For the nine months, sales was USD 19.81 million compared to USD 13.6 million a year ago. Net loss was USD 17.23 million compared to USD 9.35 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 1.07 compared to USD 0.38 a year ago.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Companyâs products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
PROSOMNUS, INC. 
